One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
10:11 PM
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

QTTB

Q32 Bio Inc

Last Close
Mar 13 • 04:00PM ET
1.84
Dollar change
-0.06
Percentage change
-3.16%
Healthcare • Biotechnology • USA • NASD
Dividends
Earnings
Revenue
Forecast

Data

Timeframe

Next report dateJun 11, 2025 (Est)
Report periodQ1 2025
EPS Est.-$1.23
GAAP EPS Est.—
Revenue Est.$0.00

EPS Performance and Forecast

-12.00-9.00-6.00-3.000.00
Currency: USDQ1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
-9.54-8.51-7.56-5.40-1.42-1.00-1.38-1.53-1.23-1.26-1.24-0.79
# of Analysts741123432222
-9.00-10.98-10.26-3.31-6.33-1.42-1.46-1.16————
0.54
-5.66%		-2.47
29.10%		-2.70
35.71%		2.09
-38.70%		-4.92
347.35%		-0.42
42.47%		-0.08
5.87%		0.37
-24.20%		————

GAAP EPS Performance and Forecast

-12.00-9.00-6.00-3.000.00
Currency: USDQ1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
-9.63-9.18-7.56-4.86-1.02-1.12-1.40-1.45————
# of Analysts21111231————
-9.00-10.98-7.56-3.31-2.95-1.42-1.46-1.46————
0.63
-6.54%		-1.80
19.61%		0.00
-0.00%		1.55
-31.89%		-1.92
188.73%		-0.30
27.35%		-0.06
4.04%		-0.01
0.69%		————

Revenue Performance and Forecast

0.00300K600K900K1M
Currency: USDQ1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
1.01M830.50K500.00K500.00K0.000.000.000.000.000.000.000.00
# of Analysts741124532222
802.00K354.00K500.00K—0.000.000.000.00————
-212.60K
-20.95%		-476.50K
-57.38%		0.00
0.00%		—0.000.000.000.00————

Price Reaction to Earnings Reports

Report Date-3 Days-2 Days-1 DayOpenHighLowClose+1 Day+2 Days+3 Days+1 Week-1 Week
Mar 11, 2025 BMO
2.332.222.062.052.051.891.901.901.84——2.16
Q4 ‘24 (Dec ‘24)
QTTB %
+3.79%-4.72%-7.21%
-0.49%
-0.49%
-8.50%
-7.77%
0.00%-3.16%——0.00%
RSI
26
SPY %
-1.78%+0.56%-2.66%-0.21%+0.61%-1.53%-0.83%+0.53%-1.33%——-1.18%
Nov 07, 2024 BMO
46.8447.7248.0049.1951.2646.6047.4645.2945.0143.6835.6347.23
Q3 ‘24 (Sep ‘24)
QTTB %
-1.24%+1.88%+0.59%
+2.48%
+6.79%
-2.92%
-1.13%
-4.57%-0.62%-2.95%-10.32%+1.96%
RSI
54
SPY %
-0.22%+1.21%+2.49%+0.35%+0.95%+0.33%+0.77%+0.43%+0.10%-0.31%-0.64%-1.96%
Aug 08, 2024 BMO
38.1037.1340.1041.0441.0433.8735.8334.4335.9035.6636.6737.97
Q2 ‘24 (Jun ‘24)
QTTB %
+0.61%-2.55%+8.00%
+2.34%
+2.34%
-15.54%
-10.65%
-3.91%+4.27%-0.67%+0.94%-0.29%
RSI
76
SPY %
-2.91%+0.92%-0.67%+1.01%+2.44%+0.61%+2.31%+0.44%+0.05%+1.64%+1.71%-1.42%
May 09, 2024 BMO
25.8527.1926.2825.3627.5024.1726.8027.1327.7528.4231.0025.77
Q1 ‘24 (Mar ‘24)
QTTB %
+1.02%+5.18%-3.35%
-3.50%
+4.64%
-8.03%
+1.98%
+1.23%+2.29%+2.41%+5.44%-2.90%
RSI
57
SPY %
+1.03%+0.11%+0.01%+0.04%+0.58%-0.09%+0.58%+0.13%+0.01%+0.46%-0.21%+0.94%
Mar 13, 2024
16.0216.3816.1615.8916.4515.6716.3816.6916.4816.2016.2916.37
Q4 ‘23 (Dec ‘23)
QTTB %
-1.40%+2.26%-1.36%
-1.62%
+1.84%
-3.01%
+1.39%
+1.90%-1.25%-1.71%+0.52%+3.20%
RSI
66
SPY %
-0.60%-0.09%+1.08%+0.06%+0.10%-0.44%-0.16%-0.20%-0.99%+0.59%+0.92%+0.51%
Nov 14, 2023 AMC
18.1818.5418.3617.5717.5714.9415.8410.3010.089.989.9218.72
Q3 ‘23 (Sep ‘23)
QTTB %
0.00%+1.98%-0.97%
-4.29%
-4.29%
-18.63%
-13.74%
-34.99%-2.08%-1.00%-1.59%+1.96%
RSI
45
SPY %
+1.56%-0.10%+1.94%+0.31%+0.59%+0.02%+0.21%+0.12%+0.12%+0.77%+0.39%+0.07%
Aug 14, 2023 AMC
21.4221.0621.2420.5222.8620.5221.6020.1619.6219.4420.7022.68
Q2 ‘23 (Jun ‘23)
QTTB %
-4.80%-1.68%+0.85%
-3.39%
+7.63%
-3.39%
+1.69%
-6.67%-2.68%-0.92%+1.77%-1.56%
RSI
52
SPY %
+0.04%-0.06%+0.55%-0.41%-0.33%-1.30%-1.16%-0.73%-0.76%+0.05%-0.27%-0.43%
May 11, 2023 AMC
18.3617.6417.9117.8218.3617.3117.6818.3618.9018.7219.0818.00
Q1 ‘23 (Mar ‘23)
QTTB %
+0.99%-3.91%+1.54%
-0.52%
+2.49%
-3.40%
-1.33%
+3.87%+2.94%-0.95%+1.92%+1.77%
RSI
48
SPY %
-0.44%+0.47%-0.17%+0.31%+0.37%-0.74%-0.13%+0.35%-0.67%+1.21%-0.15%+1.85%
Mar 09, 2023 AMC
27.1826.6424.1227.0027.0020.7022.1419.6219.2618.1817.1025.74
Q4 ‘22 (Dec ‘22)
QTTB %
+5.59%-1.99%-9.46%
+11.94%
+11.94%
-14.18%
-8.21%
-11.38%-1.83%-5.61%-3.06%-1.38%
RSI
43
SPY %
-1.53%+0.16%-1.84%-0.15%+0.41%-1.85%-1.44%-0.14%+1.65%-0.63%-1.55%+1.60%
Nov 10, 2022 AMC
25.2024.3025.3825.2027.9025.2027.0028.8031.8636.7234.3825.92
Q3 ‘22 (Sep ‘22)
QTTB %
-2.78%-3.57%+4.44%
-0.71%
+9.93%
-0.71%
+6.38%
+6.67%+10.63%+15.25%-4.98%+1.41%
RSI
41
SPY %
+0.54%-2.06%+5.50%+0.23%+1.18%-0.27%+0.97%-0.85%+0.85%-0.76%+0.45%+1.44%
Aug 15, 2022 AMC
51.3049.6852.0254.3655.0850.4052.0250.0448.2444.4647.8844.10
Q2 ‘22 (Jun ‘22)
QTTB %
-0.35%-3.16%+4.71%
+4.50%
+5.88%
-3.11%
0.00%
-3.81%-3.60%-7.84%+9.47%-16.67%
RSI
61
SPY %
0.00%+1.69%+0.41%-0.26%+0.67%-0.46%+0.20%-0.71%+0.29%-1.34%-0.24%-0.40%
May 16, 2022 AMC
28.2625.2025.9225.7427.9025.7427.1825.3829.7027.9025.0233.12
Q1 ‘22 (Mar ‘22)
QTTB %
-2.48%-10.83%+2.86%
-0.69%
+7.64%
-0.69%
+4.86%
-6.62%+17.02%-6.06%-6.08%+10.18%
RSI
32
SPY %
-0.10%+2.39%-0.41%+1.61%+2.12%+0.62%+2.06%-4.03%-0.61%+0.04%-0.76%+0.23%
Daily change and RSI 14 are based on the report date for BMO releases and the following day for AMC releases.
38%
EPS beats the estimate
3/8 last quarters
25%
GAAP EPS beats the estimate
2/8 last quarters
0%
Revenue beats the estimate
0/8 last quarters

Latest Revisions

Estimate

Q4 ‘24
Estimate
-1.51
Up Revisions
0/4
Down Revisions
0/4
Revision Date
Mar 03, 2025
Q1 ‘25
Estimate
-1.23
Up Revisions
1/2
Down Revisions
0/2
Revision Date
Mar 11, 2025
FY ‘24
Estimate
-5.54
Up Revisions
0/4
Down Revisions
0/4
Revision Date
Mar 03, 2025
FY ‘25
Estimate
-4.20
Up Revisions
2/3
Down Revisions
0/3
Revision Date
Mar 11, 2025

Estimate Revisions

Period

AprMayJunJulAugSepOctNovDec25FebMar-6.65-5.70-4.75-3.80-2.85-1.90● EPS Estimate0.0010.0020.0030.0040.0050.00● Close Price
02468
Peers: VRTX SRPT CRSP ARGX BMRN PTCT XENE EDIT MDGL GTX
 | Held by: VTI IWM VXF IWN VTWO IBB IWC VTWV RSSL IWV
Scroll to Statements
IndexRUT P/E- EPS (ttm)-10.37 Insider Own63.80% Shs Outstand12.20M Perf Week-21.03%
Market Cap22.45M Forward P/E- EPS next Y-4.23 Insider Trans0.00% Shs Float4.41M Perf Month-36.11%
Income-47.73M PEG- EPS next Q-1.23 Inst Own36.60% Short Float23.25% Perf Quarter-91.88%
Sales0.00M P/S- EPS this Y36.17% Inst Trans19.17% Short Ratio3.00 Perf Half Y-96.16%
Book/sh0.47 P/B3.95 EPS next Y-0.61% ROA-23.96% Short Interest1.03M Perf Year-88.77%
Cash/sh6.39 P/C0.29 EPS next 5Y6.40% ROE-121.36% 52W Range1.85 - 53.79 Perf YTD-46.51%
Dividend Est.- P/FCF- EPS past 5Y31.75% ROI-228.75% 52W High-96.58% Beta-0.22
Dividend TTM- Quick Ratio4.97 Sales past 5Y184.31% Gross Margin- 52W Low-0.54% ATR (14)0.26
Dividend Ex-Date- Current Ratio4.97 EPS Y/Y TTM91.45% Oper. Margin- RSI (14)22.96 Volatility10.07% 8.55%
Employees42 Debt/Eq3.33 Sales Y/Y TTM-100.00% Profit Margin- Recom2.33 Target Price13.67
Option/ShortYes / Yes LT Debt/Eq2.68 EPS Q/Q76.71% Payout- Rel Volume0.52 Prev Close1.90
Sales Surprise- EPS Surprise24.20% Sales Q/Q- EarningsMar 11 BMO Avg Volume341.35K Price1.84
SMA20-20.10% SMA50-36.08% SMA200-92.65% Trades Volume179,099 Change-3.16%
Date Action Analyst Rating Change Price Target Change
Feb-11-25Downgrade Piper Sandler Overweight → Neutral $20 → $4
Feb-11-25Downgrade BMO Capital Markets Outperform → Market Perform $22 → $3
Dec-11-24Downgrade Wells Fargo Overweight → Equal Weight $95 → $16
Dec-11-24Downgrade Raymond James Strong Buy → Outperform $90 → $22
Dec-11-24Downgrade Leerink Partners Outperform → Market Perform $68 → $9
Dec-11-24Downgrade Guggenheim Buy → Neutral
Dec-06-24Initiated BMO Capital Markets Outperform $64
Oct-24-24Initiated Raymond James Strong Buy $90
Sep-11-24Initiated Wells Fargo Overweight $95
Jun-17-24Initiated Guggenheim Buy $100
Show Previous Ratings
Mar-11-25 06:59AM
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
(PR Newswire) -7.77%
Mar-08-25 11:00AM
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
(PR Newswire)
Feb-28-25 09:00AM
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
(PR Newswire)
Feb-26-25 06:59AM
Q32 Bio to Participate in Upcoming March Investor Conferences
(PR Newswire) -5.26%
Feb-10-25 04:05PM
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
(PR Newswire) -9.43%
04:05PM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Feb-04-25 04:05PM
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
(PR Newswire) +7.95%
Dec-12-24 07:45AM
Q32 Bio price target lowered to $20 from $80 at Oppenheimer
(TipRanks) -28.57%
Dec-11-24 04:11PM
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment
(Investor's Business Daily) -75.62%
09:42AM
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
(Investor's Business Daily)
Dec-10-24 04:05PM
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
(PR Newswire) +7.68%
Nov-07-24 06:59AM
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-05-24 06:59AM
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
(PR Newswire)
Oct-14-24 06:59AM
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
(PR Newswire)
Aug-29-24 06:59AM
Q32 Bio to Participate in Upcoming September Investor Conferences
(PR Newswire)
Jul-09-24 06:59AM
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
(PR Newswire) +7.89%
06:59AM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Jul-01-24 06:59AM
Q32 Bio Joins Russell 3000 Index
(PR Newswire) +5.74%
May-09-24 01:56PM
QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024
(InvestorPlace)
06:59AM
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
(PR Newswire)
Apr-03-24 07:00AM
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
(PR Newswire)
Mar-18-24 04:30PM
Homology Medicines Declares Distribution to Common Stockholders
(GlobeNewswire)
Mar-15-24 09:52PM
FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023
(InvestorPlace)
Mar-01-24 10:48AM
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
(GlobeNewswire)
Jan-27-24 12:10PM
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX
(GlobeNewswire)
Jan-03-24 04:08PM
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
(GlobeNewswire) +5.43%
Nov-17-23 06:40AM
Q32 Bio to merge with Homology Medicines
(Pharmaceutical Business Review)
Nov-16-23 12:18PM
Homology enters reverse merger with Q32 Bio
(BioPharma Dive) -34.99%
07:05AM
Q32 Bio and Homology Medicines Announce Merger Agreement
(PR Newswire)
Nov-14-23 05:02PM
Homology Medicines: Q3 Earnings Snapshot
(Associated Press Finance) -13.74%
04:33PM
Homology Medicines Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Aug-14-23 04:20PM
Homology Medicines: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
04:05PM
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire)
Jul-27-23 04:05PM
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
(GlobeNewswire) -8.74% +41.49%
04:01PM
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
(GlobeNewswire)
Jul-06-23 11:17AM
12 Best Nano Cap Stocks To Buy Now
(Insider Monkey) -5.02%
May-16-23 08:00AM
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
(GlobeNewswire)
May-11-23 05:35PM
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
04:25PM
Homology Medicines: Q1 Earnings Snapshot
(AP Finance)
04:05PM
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
(GlobeNewswire)
May-03-23 07:30AM
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
(GlobeNewswire) +5.71%
Mar-27-23 05:52AM
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?
(Zacks)
Mar-15-23 04:01PM
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
(GlobeNewswire) -5.61%
Mar-09-23 06:45PM
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks) -9.46% -8.21%
04:05PM
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
(GlobeNewswire)
08:00AM
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
(GlobeNewswire)
Mar-02-23 07:30AM
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
(GlobeNewswire) -8.23%
Feb-24-23 05:31AM
Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock three years ago
(Simply Wall St.) -13.12%
Feb-22-23 04:01PM
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium Meeting
(GlobeNewswire) +19.40%
Jan-05-23 09:25AM
Homology Medicines Provides Update From Gene Therapy Trials
(Benzinga) +14.62%
Jan-04-23 04:01PM
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
(GlobeNewswire) +8.33%
Nov-12-22 08:08AM
Homology Medicines Third Quarter 2022 Earnings: Misses Expectations
(Simply Wall St.)
Nov-10-22 05:45PM
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates
(Zacks) +6.38%
04:07PM
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
(GlobeNewswire)
Oct-27-22 09:00AM
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
(GlobeNewswire)
Oct-06-22 08:30AM
Homology Medicines to Participate at Upcoming Conferences
(GlobeNewswire)
Sep-27-22 08:15AM
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
(GlobeNewswire) +5.26%
Sep-08-22 11:05AM
The Petri Dish: Homology gets new CEO amid shakeup; two Boston firms join 'pandemic readiness' lobby
(American City Business Journals)
Sep-06-22 04:01PM
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
(GlobeNewswire)
Aug-17-22 01:05PM
Bedford's Homology Medicine lays off 10 as it puts a program on pause
(American City Business Journals)
Aug-16-22 11:52AM
Homology Medicines Pauses Enrollment For Rare Inherited Disorder Study
(Benzinga)
Aug-15-22 06:15PM
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
04:10PM
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
(GlobeNewswire)
Aug-12-22 07:46AM
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder
(Benzinga)
Aug-11-22 04:05PM
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
(GlobeNewswire)
Jul-25-22 09:12AM
Homology Medicines (NASDAQ:FIXX) investors are sitting on a loss of 87% if they invested three years ago
(Simply Wall St.)
Jul-05-22 08:30AM
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
(GlobeNewswire) +5.46%
Jun-29-22 08:00AM
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
(GlobeNewswire)
Jun-13-22 08:00AM
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
(GlobeNewswire) -9.77%
Jun-10-22 08:30AM
What Type Of Shareholders Make Up Homology Medicines, Inc.'s (NASDAQ:FIXX) Share Registry?
(Simply Wall St.) -6.11%
May-18-22 06:00AM
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
(GlobeNewswire) -6.62%
May-16-22 06:05PM
Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:15PM
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
(GlobeNewswire)
May-13-22 08:45AM
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) -10.83%
May-02-22 04:56PM
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
(GlobeNewswire) +5.29%
Apr-21-22 08:30AM
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
(GlobeNewswire) -7.29%
Mar-23-22 05:45PM
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks) -6.32%
04:10PM
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
(GlobeNewswire)
Mar-10-22 04:01PM
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
(GlobeNewswire)
Mar-08-22 10:00AM
Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing
(Zacks)
Mar-07-22 09:38AM
Why Homology Medicines (FIXX) Might Surprise This Earnings Season
(Zacks)
Mar-03-22 03:00PM
Homology Medicines (FIXX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks) -9.19%
07:30AM
Homology Medicines to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-24-22 08:45AM
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
05:39AM
The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs
(American City Business Journals)
Feb-23-22 10:00AM
Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks
(Zacks) +7.31%
Feb-22-22 07:34AM
Homology Medicines Stock Plunges After FDA Clinical Hold On Gene Therapy Trial
(Benzinga) -32.64%
Feb-21-22 09:40AM
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
(Zacks)
02:53AM
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
(Zacks)
Feb-18-22 04:05PM
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
(GlobeNewswire) -32.64%
Feb-10-22 11:40AM
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium Meeting
(GlobeNewswire) -5.30%
07:18AM
Homology Medicines (NASDAQ:FIXX) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 83%
(Simply Wall St.)
Feb-02-22 09:40AM
Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year?
(Zacks)
Jan-28-22 10:46AM
Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings
(Benzinga)
02:30AM
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
(GlobeNewswire)
Jan-21-22 09:38AM
Concord Wealth Partners Buys Schwab Intermediate-Term U.S. ...
(GuruFocus.com)
Dec-12-21 08:19AM
Companies Like Homology Medicines (NASDAQ:FIXX) Are In A Position To Invest In Growth
(Simply Wall St.)
Dec-10-21 06:38PM
Franklin U.S. Small Capitalization Equity Fund Buys Ovintiv Inc, ShockWave Medical Inc, SM ...
(GuruFocus.com)
Nov-15-21 07:10AM
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
(GlobeNewswire)
Nov-03-21 08:29AM
Homology Medicines to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Nov-01-21 03:01PM
Will Homology Medicines (FIXX) Report Negative Q3 Earnings? What You Should Know
(Zacks)
Oct-21-21 07:00AM
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
(GlobeNewswire)
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Institutional Ownership

ORBIMED ADVISORS LLC18.50%
Atlas Venture Life Science Advisors, LLC17.18%
Carlyle Group Inc.9.05%
ACORN CAPITAL ADVISORS, LLC6.60%
Sio Capital Management, LLC5.73%
Monaco Asset Management SAM4.72%
BlackRock, Inc.3.84%
ARCH Venture Management, LLC2.63%
VANGUARD GROUP INC2.60%
Temasek Holdings2.58%
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period End Date12/31/202412/31/202312/31/202212/31/202112/31/202012/31/201912/31/2018
Period Length12 Months12 Months12 Months

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
0.000.00-6.65
Cost of Goods Sold Incl. D&A
0.490.490.50
Gross Profit
-0.49-0.49-7.15
Selling, General and Administrative Excl. Other
65.6165.6141.10
Research and Development
48.1448.1431.73
Other Operating Expense
0.000.000.00
Operating Income
-66.10-66.10-48.26
Interest Expense
0.301.50
Unusual Expense
-16.01-17.396.19
Net Income Before Taxes
-46.09-46.09-53.42
Income Taxes
0.020.020.32
Consolidated Net Income
-47.73-47.73-53.74
Net Income From Continuing Operations
-47.73-47.73-53.74
Net Income
-47.73-47.73-53.74
EPS (Recurring)
-6.14-7.84-141.55
EPS (Basic, Before Extraordinaries)
-3.01-5.12-153.97
EPS (Diluted)
-10.37-6.58-153.97
EBITDA
-65.61-65.61-47.76
Price To Earnings Ratio
-0.13-0.13-0.22
Price To Sales Ratio
30.42
Gross Margin
107.50
Operating Margin
725.53
Net Margin
808.04
Shares Outstanding
12.2012.200.36
Market Capitalization
23.1423.1437.88
values in Millions, USD
Insider Trading Volume
MarAprMayJunJulAugSepOctNovDec25FebMar0.004.00K8.00K12.00K16.00KUSD Trades Volume$0.00$15.00$30.00$45.00$60.00● Close Price
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Violette Shelia M.Chief Scientific OfficerOct 15 '24Option Exercise7.296,00043,74023,874Oct 16 08:39 PM
Violette Shelia M.Chief Scientific OfficerOct 11 '24Option Exercise3.124,57414,27117,874Oct 16 08:39 PM
Violette Shelia M.Chief Scientific OfficerOct 08 '24Option Exercise3.1213,30041,49613,300Oct 10 04:05 PM
TZIANABOS ARTHURDirectorMar 25 '24Sale24.202656,4137,983Aug 14 04:05 PM
Alloway PaulSee RemarksMar 25 '24Sale24.212686,4882,596Apr 23 05:03 PM
Michaud Charles JrSee RemarksMar 25 '24Sale24.20751,815927Apr 23 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.